Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS

BACKGROUND Gray matter (GM) pathology is an important component of the multiple sclerosis (MS) disease process. Accelerated gray matter atrophy has been observed in MS patients, but its relationship to neurological disability is not defined. This study was done to determine the relationship between whole brain, GM, and white matter (WM) atrophy and MS disability progression. METHODS Patients with MS and Clinically Isolated Syndromes (CIS), and age- and gender-matched healthy controls were entered into an observational protocol. Baseline brain parenchymal fraction (BPF), GM fraction, and WM fraction, and change over 4 years were correlated with sustained disability progression over the entire study duration. Disability progression was measured using the Multiple Sclerosis Functional Composite (MSFC) and the Expanded Disability Status Scale (EDSS). RESULTS Seventy MS and CIS patients and 17 HCs were studied for an average of 6.6 years (range, 3.6-7.8 years). At the final visit, 7 patients were classified as CIS, 36 as relapsing-remitting MS (RRMS), and 27 as secondary progressive MS (SPMS). Baseline whole brain, GM, and WM atrophy predicted EDSS >6.0 at the last study visit. Twenty-one (33%) patients worsened using the EDSS to define disability progression; 29 (46%) worsened using MSFC to define disability progression. Patients with MSFC progression had significantly higher GM atrophy rates compared with patients who were stable on MSFC. White matter atrophy was similar in patients with and without disability progression. Atrophy rates were not different in patients with or without disability progression defined using EDSS. CONCLUSIONS Whole brain, GM, and WM atrophy predicted MS disability progression observed over the next 6.6 years. Gray matter atrophy rates over 4 years correlated with disability progression measured with the MSFC, but not EDSS. This indicates that MSFC defined disability progression is more closely linked to brain atrophy than EDSS defined disability progression, and provides important new insight into the poor correlation between MRI and clinical disability in MS. The findings confirm the clinical relevance of gray matter atrophy in MS.

[1]  A J Thompson,et al.  Gray and white matter volume changes in early RRMS , 2005, Neurology.

[2]  D. Mattson,et al.  The measurement of ambulatory impairment in multiple sclerosis , 1997, Neurology.

[3]  L G Nyúl,et al.  Relapsing-remitting Multiple Sclerosis: Fractional Volumetric Analysis of Gray Matter and White Matter , 2000 .

[4]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[5]  Robert Zivadinov,et al.  Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. , 2006, Archives of neurology.

[6]  Ludwin Sk,et al.  The neuropathology of multiple sclerosis. , 2000 .

[7]  Alan J. Thompson,et al.  Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis , 2004, NeuroImage.

[8]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[9]  A J Thompson,et al.  Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis , 2003, Multiple sclerosis.

[10]  Marco Rovaris,et al.  Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[11]  N. De Stefano,et al.  Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment , 2004, Neurology.

[12]  Rohit Bakshi,et al.  Gray matter involvement in multiple sclerosis , 2007, Neurology.

[13]  Nick C Fox,et al.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS , 2000, Neurology.

[14]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[15]  G J Barker,et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.

[16]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[17]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[18]  Kunio Nakamura,et al.  Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients , 2009, NeuroImage.

[19]  C. Lederer,et al.  Disability as an outcome in MS clinical trials , 2008, Neurology.

[20]  G Tedeschi,et al.  Brain atrophy and lesion load in a large population of patients with multiple sclerosis , 2005, Neurology.

[21]  Hans Lassmann,et al.  Cortical lesions and brain atrophy in MS , 2005, Journal of the Neurological Sciences.

[22]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[23]  H. Adams,et al.  Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.

[24]  Rohit Bakshi,et al.  The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.

[25]  F. Barkhof,et al.  Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.

[26]  G Cutter,et al.  Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. , 2000, Multiple sclerosis.

[27]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[28]  M Rovaris,et al.  Whole brain volume changes in patients with progressive MS treated with cladribine , 2000, Neurology.

[29]  F. Roncaroli,et al.  Neuropathology of multiple sclerosis , 2012 .

[30]  Marco Rovaris,et al.  Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. , 2005, Archives of neurology.

[31]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[32]  N. Abdelrahman,et al.  Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis , 2008, American Journal of Neuroradiology.

[33]  David H. Miller,et al.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.

[34]  J. Folch-Pi.  Chemical Pathology of the Nervous System , 1962 .

[35]  R. Rudick,et al.  Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.

[36]  Marco Battaglini,et al.  Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. , 2007, Archives of neurology.

[37]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[38]  Jeffrey A. Cohen,et al.  Multiple Sclerosis Therapeutics , 1999 .

[39]  Measurement of central nervous system atrophy in multiple sclerosis , 2007 .

[40]  O. Kantarci,et al.  Gray Matter Atrophy Is Related to Long-Term Disability in Multiple Sclerosis , 2009 .